A glycolipid way to say no to Diabetes Mellitus: α-Galactosylceramide, a synthetic glycolipid, augments the expression of FGF19 and FGF1, attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via up regulation of its target gene, 29/April/2018, 6.56 am